SNCA and cancer: Therefore CRISPR-Cas9 mediated deletion of PD-1 may potentially enhance the effects of cytotoxicity and T-cell immune responses against cancer, with clinical trials underway to ascertain if this is a viable strategy against prostate cancer [152].